Lexaria Bioscience (LEXX US)

Analysis

Health Care • Canada

Lexaria Bioscience Corp improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier ingestion methods. The Company's technology can be applied to ingestible product formats such as foods, beverages, oral suspensions, tablets, and capsules. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio.

Refresh

Exchange Announcement • 14 Oct 2026 05:15

424B3 | Prospectus

Exchange Announcement • 09 Sep 2026 22:12

Current Report (Form 8-K | Period ending 2026-09-07)

Exchange Announcement • 01 Sep 2026 21:16

Current Report (Form 8-K | Period ending 2026-08-28)

Exchange Announcement • 18 Aug 2026 00:37

Current Report (Form 8-K | Period ending 2026-08-17)

Exchange Announcement • 11 Aug 2026 05:00

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

424B3 | Prospectus

Current Report (Form 8-K | Period ending 2026-09-07)

Current Report (Form 8-K | Period ending 2026-08-28)

Current Report (Form 8-K | Period ending 2026-08-17)

Current Report (Form 8-K | Period ending 2026-08-04)